Author: Yasir Mahmood
Introduction of online MDMC licensing and product registration portal
Notification of draft amendments in the Drugs (Labelling and Packing) Rules 1986
Draft amendments to the Drugs (Labelling and Packing) Rules, 1986, have been published for public information. Comments or suggestions, if any, may be forwarded to director.legal∂dra.gov.pk within seven days of the publication of this notification.
Disposal of Import cases of Alternative Medicines with short shelf life
Annual Schedule for the CSC Meetings for the year 2025
The Clinical Studies Committee (CSC) of Drug Regulatory Authority of Pakistan (DRAP) is mandated under Bio Study Rules 2017 for the regulatory oversight of clinical trials and clinical studies related to therapeutic goods in the country. The CSC reviews and approves clinical study protocols, ensuring they adhere to ethical and scientific standards. It also monitors ongoing clinical trials to assess participant safety and efficacy, makes informed decisions regarding study design, and collaborates with researchers, sponsors, and other stakeholders to ensure quality clinical research and safety of the participants.
The Committee has decided that the CSC meetings will be convened after every 45 days and an annual CSC meeting schedule for 2025 (tentative) has been issued with the aims to enhance transparency, efficiency, and collaboration.
| S. No. | CSC Meeting | Proposed Date |
| 01 | 54th CSC Meeting | 28th – 31st January 2025 |
| 02 | 55th CSC Meeting | 03rd – 08th March 2025 |
| 03 | 56th CSC Meeting | 21st – 25th April 2025 |
| 04 | 57th CSC Meeting | 26th – 31st May 2025 |
| 05 | 58th CSC Meeting | 07th – 11th July 2025 |
| 06 | 59th CSC Meeting | 25th – 29th August 2025 |
| 07 | 60th CSC Meeting | 01st – 03rd October 2025 |
| 08 | 61st CSC Meeting | 08th – 12th December 2025 |
Vacancy Announcement for the position of Chief Executive Officer, Drug Regulatory Authority of Pakistan
Request for Expression of Interest (EOI)
Invitation to bid: Provision of housekeeping, janitorial & support staff at DRAP offices
Draft Guidance Document For Clinical Trials Of Biological Products (Manufacture Locally)
For comments of stakeholders
Caution Regarding Fake Emails Impersonating DRAP Officials
It has come to our attention that some individuals are receiving fraudulent emails impersonating officials of the Drug Regulatory Authority of Pakistan (DRAP). Please be advised that all official DRAP correspondence comes from email addresses ending with @dra.gov.pk.
Stakeholders and the public are urged to remain vigilant and verify the authenticity of any communication. If in doubt, kindly contact DRAP through official channels.
Thank you for your attention to this matter.
Drug Regulatory Authority of Pakistan